AbbVieABBV
A drugmaker whose medicines include Skyrizi and Rinvoq for immune diseases, and Botox; its former top seller, Humira, now competes with cheaper copies.
By financial year
| Figure | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Income | |||||
| Revenue | $56.2bn | $58.1bn | $54.3bn | $56.3bn | $61.2bn |
| Gross profit | $38.8bn | $40.6bn | $33.9bn | $39.4bn | $43.0bn |
| Operating income | $17.9bn | $18.1bn | $12.8bn | $9.1bn | $15.1bn |
| Net income | $11.5bn | $11.8bn | $4.9bn | $4.3bn | $4.2bn |
| Earnings per share (diluted) | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 |
| Cash flow | |||||
| Cash from operations | $22.8bn | $24.9bn | $22.8bn | $18.8bn | $19.0bn |
| Capital spending | $787m | $695m | $777m | $974m | $1.2bn |
| Free cash flow | $22.0bn | $24.2bn | $22.1bn | $17.8bn | $17.8bn |
| Share buybacks | $934m | $1.5bn | $2.0bn | $1.7bn | $980m |
| Balance sheet (at the end of the period) | |||||
| Cash and investments | $9.8bn | $9.2bn | $12.8bn | $5.6bn | $5.3bn |
| Total debt | $76.0bn | $63.1bn | $59.2bn | $66.8bn | $67.0bn |
| Net debt (debt less cash) | $66.1bn | $53.9bn | $46.4bn | $61.3bn | $61.7bn |
| Shareholders’ equity | $15.4bn | $17.3bn | $10.4bn | $3.3bn | −$3.3bn |
| Shares (diluted average) | 1.78bn | 1.78bn | 1.77bn | 1.77bn | 1.77bn |
By quarter
| Figure | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | $15.1bn | $13.3bn | $15.4bn | $15.8bn | $16.6bn | $15.0bn | $17.0bn | $17.4bn |
| Gross profit | $10.7bn | $9.3bn | $11.1bn | $10.5bn | $12.1bn | $10.8bn | $12.7bn | $13.1bn |
| Operating income | −$1.5bn | $3.7bn | $4.9bn | $1.9bn | $4.5bn | $4.0bn | $6.4bn | $6.3bn |
| Net income | −$22m | $1.3bn | $938m | $186m | $1.8bn | $695m | $3.6bn | $4.2bn |
| Earnings per share (diluted) | −$0.02 | $0.72 | $0.52 | $0.10 | $1.02 | $0.39 | $2.03 | $2.37 |
| Cash flow | ||||||||
| Cash from operations | $7.0bn | $1.6bn | $5.2bn | $7.0bn | $5.2bn | $3.8bn | $3.4bn | $7.6bn |
| Capital spending | $291m | $235m | $269m | $381m | $329m | $265m | $322m | $301m |
| Free cash flow | $6.8bn | $1.4bn | $4.9bn | $6.6bn | $4.9bn | $3.6bn | $3.1bn | $7.3bn |
| Share buybacks | $358m | $961m | $12m | $4m | $3m | $1.5bn | $9m | $5m |
| Balance sheet (at the end of the period) | ||||||||
| Cash and investments | $5.6bn | $5.2bn | $6.5bn | $5.7bn | $5.3bn | $9.4bn | $6.6bn | $10.8bn |
| Total debt | $66.8bn | $69.9bn | $70.5bn | $68.7bn | $67.0bn | $72.9bn | $70.8bn | $80.9bn |
| Net debt (debt less cash) | $61.3bn | $64.7bn | $64.0bn | $63.1bn | $61.7bn | $63.5bn | $64.3bn | $70.1bn |
| Shareholders’ equity | $3.3bn | $1.4bn | −$183m | −$2.6bn | −$3.3bn | −$6.7bn | −$5.9bn | −$4.6bn |
| Shares (diluted average) | — | 1.77bn | 1.77bn | 1.77bn | — | 1.77bn | 1.77bn | 1.77bn |
Charts and live prices are delayed, from TradingView. Market values use each company’s last trade on IEX at the previous close, times the shares in issue from its filings; company figures come from SEC filings. This is information, not investment advice. Where our market data comes from
Company logos are trademarks of their owners, shown only to identify them; the files are from Wikimedia Commons.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.